AMPLIA THERAPEUTICS LIMITED - Announcements

0.00%

16.0¢

Market Cap $82.09M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Announcements

Filter Results

All Price Sensitive Only

ATX	FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL	PRICE SENSITIVE	04/09/25	179.93KB	Share
ATX	Notification of cessation of securities - ATX		02/09/25	12.81KB	Share
ATX	NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA		02/09/25	168.78KB	Share
ATX	Notification regarding unquoted securities - ATX		01/09/25	18.25KB	Share
ATX	Notification regarding unquoted securities - ATX		01/09/25	18.86KB	Share
ATX	Notice under Section 708A(5)(e) of the Corporations Act		01/09/25	211.32KB	Share
ATX	Application for quotation of securities - ATX		01/09/25	15.63KB	Share
ATX	Application for quotation of securities - ATX		01/09/25	15.64KB	Share
ATX	AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL		29/08/25	168.46KB	Share
ATX	Application for quotation of securities - ATX		29/08/25	15.71KB	Share
ATX	Results of Annual General Meeting		27/08/25	204.53KB	Share
ATX	Managing Director's Presentation to AGM		27/08/25	3.36MB	Share
ATX	Amplia Share Purchase Plan Raises $2.65 Million	PRICE SENSITIVE	26/08/25	232.42KB	Share
ATX	Presentation - Targeting Pancreatic Cancer and Beyond		07/08/25	7.87MB	Share
ATX	Positive ACCENT Trial Topline Data Released	PRICE SENSITIVE	06/08/25	5.76MB	Share
ATX	Share Purchase Plan Prospectus		01/08/25	404.61KB	Share
ATX	Change of Registered Office and Principal Place of Business		01/08/25	129.72KB	Share
ATX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	283.77KB	Share
ATX	Ceasing to be a substantial holder - Blueflag Holdings		30/07/25	102.46KB	Share
ATX	Change in substantial holding		30/07/25	169.59KB	Share
ATX	Change in substantial holding		30/07/25	85.34KB	Share
ATX	Australian Ethics Clearance for Pancreatic Cancer Trial		30/07/25	168.47KB	Share
ATX	Notice under Section 708A(5)(e) of the Corporations Act		29/07/25	225.41KB	Share
ATX	Application for quotation of securities - ATX		29/07/25	15.9KB	Share
ATX	Notice of Annual General Meeting/Proxy Form		25/07/25	645.23KB	Share
ATX	Notice under Section 708A(5)(e) of the Corporations Act		23/07/25	225.47KB	Share
ATX	Application for quotation of securities - ATX		23/07/25	15.57KB	Share
ATX	Capital Raising Presentation	PRICE SENSITIVE	23/07/25	3.15MB	Share
ATX	Proposed issue of securities - ATX		23/07/25	15.99KB	Share
ATX	Proposed issue of securities - ATX		23/07/25	15.88KB	Share
ATX	Proposed issue of securities - ATX		23/07/25	26.74KB	Share
ATX	Amplia announces A$25m Placement and Launches A$2.5m SPP	PRICE SENSITIVE	23/07/25	238.25KB	Share
ATX	Trading Halt	PRICE SENSITIVE	21/07/25	170.35KB	Share
ATX	Another Partial Response in ACCENT Pancreatic Cancer Trial		11/07/25	170.05KB	Share
ATX	Application for quotation of securities - ATX		04/07/25	15.64KB	Share
ATX	Annual General Meeting to be held Wednesday 27 August 2025		02/07/25	121.3KB	Share
ATX	Additional Partial Response in Pancreatic Cancer Trial		02/07/25	168.04KB	Share
ATX	Amplia Gains US Ethics Approval for Pancreatic Cancer Trial		24/06/25	168.96KB	Share
ATX	Change in substantial holding		19/06/25	85.05KB	Share
ATX	Second Complete Response in ACCENT Pancreatic Cancer Trial	PRICE SENSITIVE	19/06/25	168.47KB	Share
ATX	Pathological Complete Response in Pancreatic Cancer Trial	PRICE SENSITIVE	16/06/25	171.4KB	Share
ATX	Appendix 4G - Key to Corporate Governance Disclosures		30/05/25	296.32KB	Share
ATX	2025 Corporate Governance Statement		30/05/25	349.83KB	Share
ATX	Preliminary Final Report and Annual Report YE 31 March 2025	PRICE SENSITIVE	30/05/25	19.2MB	Share
ATX	Change in substantial holding		16/05/25	189.03KB	Share
ATX	ACCENT Trial Achieves Superiority over Chemotherapy Alone	PRICE SENSITIVE	15/05/25	180.82KB	Share
ATX	Amplia Appoints Dr Jason Lickliter as Chief Medical Officer		12/05/25	171.07KB	Share
ATX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	308.18KB	Share
ATX	ACCENT Data Update Presented at International Conference		28/04/25	1.87MB	Share
ATX	US Clinical Trial Activities for Narmafotinib Now Underway		09/04/25	175.68KB	Share
ATX	Encouraging Updated Data from Pancreatic Cancer Trial		27/03/25	172.4KB	Share
ATX	Type D Meeting Outcome With US Food And Drug Administration		03/03/25	146.63KB	Share
ATX	Listing Rule 3.11.2 - change of Exercise Price of Options		13/02/25	130.91KB	Share
ATX	Completion of Recruitment of ACCENT Trial	PRICE SENSITIVE	31/01/25	175.06KB	Share
ATX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	280.81KB	Share
ATX	New Narmafotinib Data Presented at International Conference		20/01/25	695.11KB	Share
ATX	Release of Shares from Voluntary Escrow		10/01/25	116.88KB	Share
ATX	Security Class Reinstatement to Quotation - ATXOA	PRICE SENSITIVE	23/12/24	420.57KB	Share
ATX	Section 708A(5)(e) Notice - Allotment of 2,826,087 Shares		20/12/24	198.22KB	Share
ATX	Change of Director's Interest Notice - Dr Warwick Tong		20/12/24	355.83KB	Share
ATX	Change of Director's Interest Notice - Dr Chris Burns		20/12/24	352.19KB	Share
ATX	Change of Director's Interest Notice - Dr Robert Peach		20/12/24	354.5KB	Share
ATX	Change of Director's Interest Notice - Ms Jane Bell		20/12/24	326.66KB	Share
ATX	Top 20 Holders and Range of Units for Attaching Options		20/12/24	173.13KB	Share
ATX	Application for quotation of securities - ATX		20/12/24	15.62KB	Share
ATX	Application for quotation of securities - ATX		20/12/24	15.48KB	Share
ATX	Notification regarding unquoted securities - ATX		20/12/24	17.75KB	Share
ATX	Results of Meeting - EGM 19 Dec 2024		19/12/24	171.53KB	Share
ATX	Positive Data Strong Recruitment in Pancreatic Cancer Trial		11/12/24	173.51KB	Share
ATX	Application for quotation of securities - ATX		28/11/24	14.52KB	Share
ATX	Change in substantial holding		27/11/24	86.34KB	Share
ATX	App 4D and Financial Report Half Year ended 30 Sep 2024	PRICE SENSITIVE	27/11/24	874.67KB	Share
ATX	Successful Completion of Retail Entitlement Offer		27/11/24	182.21KB	Share
ATX	Security Class Suspension from Quotation	PRICE SENSITIVE	25/11/24	428.72KB	Share
ATX	Notice of Extraordinary General Meeting/Proxy Form		18/11/24	552.16KB	Share
ATX	Amplia Enters into Preclinical Collaboration		14/11/24	165KB	Share
ATX	Change in substantial holding		08/11/24	175.98KB	Share
ATX	Section 708A(5)(e) Notice - Allotment of 67,723,015 Shares		07/11/24	197.91KB	Share
ATX	Substantial Holder Notice - Blueflag Holding Pty Ltd		06/11/24	107.23KB	Share
ATX	Application for quotation of securities - ATX		06/11/24	14.42KB	Share
ATX	Proposed issue of securities - ATX		05/11/24	16.17KB	Share
ATX	Update - Proposed issue of securities - ATX		01/11/24	37.53KB	Share
ATX	Replacement Prospectus		01/11/24	650.8KB	Share
ATX	Amplia Successfully Completes Institutional Offer	PRICE SENSITIVE	01/11/24	200.59KB	Share
ATX	Proposed issue of securities - ATX		31/10/24	16.88KB	Share
ATX	Proposed issue of securities - ATX		30/10/24	38.1KB	Share
ATX	Proposed issue of securities - ATX		30/10/24	19.92KB	Share
ATX	Capital Raise Prospectus		30/10/24	515.29KB	Share
ATX	Capital Raise Presentation	PRICE SENSITIVE	30/10/24	2.67MB	Share
ATX	Amplia to Raise up to $13m for ACCENT and US Trials	PRICE SENSITIVE	30/10/24	303.61KB	Share
ATX	Interim Data From Accent Pancreatic Cancer Trial	PRICE SENSITIVE	30/10/24	869.52KB	Share
ATX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	305.47KB	Share
ATX	Trading Halt	PRICE SENSITIVE	30/10/24	543.96KB	Share
ATX	Recruitment Restarts in ACCENT Pancreatic Cancer Trial		16/10/24	168.24KB	Share
ATX	Sixth Confirmed Response in Pancreatic Cancer Trial	PRICE SENSITIVE	23/09/24	171.78KB	Share
ATX	FDA Fast Track Designation for Narmafotinib	PRICE SENSITIVE	20/09/24	162.21KB	Share
ATX	Change of Director's Interest Notice - Dr Chris Burns		26/08/24	349.83KB	Share
ATX	Application for quotation of securities - ATX		26/08/24	17.98KB	Share
ATX	Results of Annual General Meeting		23/08/24	149.42KB	Share
ATX	Managing Director AGM Presentation		23/08/24	13.1MB	Share

ATX FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL
04/09/25	PRICE SENSITIVE	179.93KB	Share
ATX Notification of cessation of securities - ATX
02/09/25		12.81KB	Share
ATX NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA
02/09/25		168.78KB	Share
ATX Notification regarding unquoted securities - ATX
01/09/25		18.25KB	Share
ATX Notification regarding unquoted securities - ATX
01/09/25		18.86KB	Share
ATX Notice under Section 708A(5)(e) of the Corporations Act
01/09/25		211.32KB	Share
ATX Application for quotation of securities - ATX
01/09/25		15.63KB	Share
ATX Application for quotation of securities - ATX
01/09/25		15.64KB	Share
ATX AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
29/08/25		168.46KB	Share
ATX Application for quotation of securities - ATX
29/08/25		15.71KB	Share
ATX Results of Annual General Meeting
27/08/25		204.53KB	Share
ATX Managing Director's Presentation to AGM
27/08/25		3.36MB	Share
ATX Amplia Share Purchase Plan Raises $2.65 Million
26/08/25	PRICE SENSITIVE	232.42KB	Share
ATX Presentation - Targeting Pancreatic Cancer and Beyond
07/08/25		7.87MB	Share
ATX Positive ACCENT Trial Topline Data Released
06/08/25	PRICE SENSITIVE	5.76MB	Share
ATX Share Purchase Plan Prospectus
01/08/25		404.61KB	Share
ATX Change of Registered Office and Principal Place of Business
01/08/25		129.72KB	Share
ATX Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	283.77KB	Share
ATX Ceasing to be a substantial holder - Blueflag Holdings
30/07/25		102.46KB	Share
ATX Change in substantial holding
30/07/25		169.59KB	Share
ATX Change in substantial holding
30/07/25		85.34KB	Share
ATX Australian Ethics Clearance for Pancreatic Cancer Trial
30/07/25		168.47KB	Share
ATX Notice under Section 708A(5)(e) of the Corporations Act
29/07/25		225.41KB	Share
ATX Application for quotation of securities - ATX
29/07/25		15.9KB	Share
ATX Notice of Annual General Meeting/Proxy Form
25/07/25		645.23KB	Share
ATX Notice under Section 708A(5)(e) of the Corporations Act
23/07/25		225.47KB	Share
ATX Application for quotation of securities - ATX
23/07/25		15.57KB	Share
ATX Capital Raising Presentation
23/07/25	PRICE SENSITIVE	3.15MB	Share
ATX Proposed issue of securities - ATX
23/07/25		15.99KB	Share
ATX Proposed issue of securities - ATX
23/07/25		15.88KB	Share
ATX Proposed issue of securities - ATX
23/07/25		26.74KB	Share
ATX Amplia announces A$25m Placement and Launches A$2.5m SPP
23/07/25	PRICE SENSITIVE	238.25KB	Share
ATX Trading Halt
21/07/25	PRICE SENSITIVE	170.35KB	Share
ATX Another Partial Response in ACCENT Pancreatic Cancer Trial
11/07/25		170.05KB	Share
ATX Application for quotation of securities - ATX
04/07/25		15.64KB	Share
ATX Annual General Meeting to be held Wednesday 27 August 2025
02/07/25		121.3KB	Share
ATX Additional Partial Response in Pancreatic Cancer Trial
02/07/25		168.04KB	Share
ATX Amplia Gains US Ethics Approval for Pancreatic Cancer Trial
24/06/25		168.96KB	Share
ATX Change in substantial holding
19/06/25		85.05KB	Share
ATX Second Complete Response in ACCENT Pancreatic Cancer Trial
19/06/25	PRICE SENSITIVE	168.47KB	Share
ATX Pathological Complete Response in Pancreatic Cancer Trial
16/06/25	PRICE SENSITIVE	171.4KB	Share
ATX Appendix 4G - Key to Corporate Governance Disclosures
30/05/25		296.32KB	Share
ATX 2025 Corporate Governance Statement
30/05/25		349.83KB	Share
ATX Preliminary Final Report and Annual Report YE 31 March 2025
30/05/25	PRICE SENSITIVE	19.2MB	Share
ATX Change in substantial holding
16/05/25		189.03KB	Share
ATX ACCENT Trial Achieves Superiority over Chemotherapy Alone
15/05/25	PRICE SENSITIVE	180.82KB	Share
ATX Amplia Appoints Dr Jason Lickliter as Chief Medical Officer
12/05/25		171.07KB	Share
ATX Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	308.18KB	Share
ATX ACCENT Data Update Presented at International Conference
28/04/25		1.87MB	Share
ATX US Clinical Trial Activities for Narmafotinib Now Underway
09/04/25		175.68KB	Share
ATX Encouraging Updated Data from Pancreatic Cancer Trial
27/03/25		172.4KB	Share
ATX Type D Meeting Outcome With US Food And Drug Administration
03/03/25		146.63KB	Share
ATX Listing Rule 3.11.2 - change of Exercise Price of Options
13/02/25		130.91KB	Share
ATX Completion of Recruitment of ACCENT Trial
31/01/25	PRICE SENSITIVE	175.06KB	Share
ATX Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	280.81KB	Share
ATX New Narmafotinib Data Presented at International Conference
20/01/25		695.11KB	Share
ATX Release of Shares from Voluntary Escrow
10/01/25		116.88KB	Share
ATX Security Class Reinstatement to Quotation - ATXOA
23/12/24	PRICE SENSITIVE	420.57KB	Share
ATX Section 708A(5)(e) Notice - Allotment of 2,826,087 Shares
20/12/24		198.22KB	Share
ATX Change of Director's Interest Notice - Dr Warwick Tong
20/12/24		355.83KB	Share
ATX Change of Director's Interest Notice - Dr Chris Burns
20/12/24		352.19KB	Share
ATX Change of Director's Interest Notice - Dr Robert Peach
20/12/24		354.5KB	Share
ATX Change of Director's Interest Notice - Ms Jane Bell
20/12/24		326.66KB	Share
ATX Top 20 Holders and Range of Units for Attaching Options
20/12/24		173.13KB	Share
ATX Application for quotation of securities - ATX
20/12/24		15.62KB	Share
ATX Application for quotation of securities - ATX
20/12/24		15.48KB	Share
ATX Notification regarding unquoted securities - ATX
20/12/24		17.75KB	Share
ATX Results of Meeting - EGM 19 Dec 2024
19/12/24		171.53KB	Share
ATX Positive Data Strong Recruitment in Pancreatic Cancer Trial
11/12/24		173.51KB	Share
ATX Application for quotation of securities - ATX
28/11/24		14.52KB	Share
ATX Change in substantial holding
27/11/24		86.34KB	Share
ATX App 4D and Financial Report Half Year ended 30 Sep 2024
27/11/24	PRICE SENSITIVE	874.67KB	Share
ATX Successful Completion of Retail Entitlement Offer
27/11/24		182.21KB	Share
ATX Security Class Suspension from Quotation
25/11/24	PRICE SENSITIVE	428.72KB	Share
ATX Notice of Extraordinary General Meeting/Proxy Form
18/11/24		552.16KB	Share
ATX Amplia Enters into Preclinical Collaboration
14/11/24		165KB	Share
ATX Change in substantial holding
08/11/24		175.98KB	Share
ATX Section 708A(5)(e) Notice - Allotment of 67,723,015 Shares
07/11/24		197.91KB	Share
ATX Substantial Holder Notice - Blueflag Holding Pty Ltd
06/11/24		107.23KB	Share
ATX Application for quotation of securities - ATX
06/11/24		14.42KB	Share
ATX Proposed issue of securities - ATX
05/11/24		16.17KB	Share
ATX Update - Proposed issue of securities - ATX
01/11/24		37.53KB	Share
ATX Replacement Prospectus
01/11/24		650.8KB	Share
ATX Amplia Successfully Completes Institutional Offer
01/11/24	PRICE SENSITIVE	200.59KB	Share
ATX Proposed issue of securities - ATX
31/10/24		16.88KB	Share
ATX Proposed issue of securities - ATX
30/10/24		38.1KB	Share
ATX Proposed issue of securities - ATX
30/10/24		19.92KB	Share
ATX Capital Raise Prospectus
30/10/24		515.29KB	Share
ATX Capital Raise Presentation
30/10/24	PRICE SENSITIVE	2.67MB	Share
ATX Amplia to Raise up to $13m for ACCENT and US Trials
30/10/24	PRICE SENSITIVE	303.61KB	Share
ATX Interim Data From Accent Pancreatic Cancer Trial
30/10/24	PRICE SENSITIVE	869.52KB	Share
ATX Quarterly Activities/Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	305.47KB	Share
ATX Trading Halt
30/10/24	PRICE SENSITIVE	543.96KB	Share
ATX Recruitment Restarts in ACCENT Pancreatic Cancer Trial
16/10/24		168.24KB	Share
ATX Sixth Confirmed Response in Pancreatic Cancer Trial
23/09/24	PRICE SENSITIVE	171.78KB	Share
ATX FDA Fast Track Designation for Narmafotinib
20/09/24	PRICE SENSITIVE	162.21KB	Share
ATX Change of Director's Interest Notice - Dr Chris Burns
26/08/24		349.83KB	Share
ATX Application for quotation of securities - ATX
26/08/24		17.98KB	Share
ATX Results of Annual General Meeting
23/08/24		149.42KB	Share
ATX Managing Director AGM Presentation
23/08/24		13.1MB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.0¢		Change 0.000(0.00%)		Mkt cap ! $82.09M

Open	High	Low	Value	Volume
16.5¢	17.5¢	16.0¢	$696.0K	4.182M

Buyers (Bids)

No.	Vol.	Price($)
16	962341	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	172361	3

View Market Depth

No.	Vol.	Price($)
16	962341	0.160
10	362471	0.155
17	1088711	0.150
3	549327	0.145
7	299463	0.140

Price($)	Vol.	No.
0.165	172361	3
0.170	22000	2
0.175	350924	7
0.180	319418	8
0.185	228570	3

Last trade - 16.10pm 04/09/2025 (20 minute delay)

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories